Sponsor content
218 result(s) found, displaying 31 to 40
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL Hong Kong Intragam NexGen HK normal immunoglobulin (human) 5g 100 g/L, 10% solution for intravenous infusion.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for HEMGENIX etranacogene dezaparvovec 1 unit solution for intravenous infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL Taiwan AlbuRx 20 TW human albumin 200g/L (20% w/v) solution for intravenous infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL Hong Kong Albumex 20 NexGen Human Albumin 200g/L Solution for Intravenous Infusion.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL New Zealand Alburex 20 NZ, Solution for infusion 20%.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL Hong Kong Aleviate Human Coagulation Factor VIII 500 IU/von Willebrand factor 1000 IU complex, Powder for injection (50 IU/mL FVIII).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL Hong Kong Aleviate Human Coagulation Factor VIII 250 IU/von Willebrand factor 500 IU complex, Powder for injection (50 IU/mL FVIII).
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CSL New Zealand Hizentra NZ Human Normal Immunoglobulin (20%) solution for subcutaneous injection.
-
Australian Public Assessment Report (AusPAR)Hemgenix (etranacogene dezaparvovec), a gene therapy, has been approved for the treatment of haemophilia B (congenital factor IX deficiency) in adults.
-
Prescription medicine decision summaryHemgenix (etranacogene dezaparvovec) has been approved for the treatment of adults with haemophilia B (congenital factor IX deficiency).